Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The month ahead: January’s remaining events
JP Morgan approaches.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
